The study was designed to evaluate combretastatin A4 phosphate (CA4P). Combretastatin represents a new class of therapeutic compounds known as vascular targeting agents.
The primary efficacy endpoint of the study was maintenance of visual acuity (defined as less than a three line loss in visual acuity at 3 months) and 100% of the patients met this endpoint. Safety results were favorable and in line with expectations, with no drug-related serious adverse events being reported.
“These results are encouraging and we believe they form a sound scientific basis for advancing our macular degeneration programs. We also believe that CA4P has the potential to be a safe and effective drug for both treatment and prophylaxis of age-related macular degeneration,” commented Richard Chin, president and CEO of Oxigene.
Oxigene announced that it has completed a pre-IND meeting with the FDA regarding two topical ophthalmic formulations, eye drops and ocular mini-tabs, for CA4P and intends to proceed with further development of topical formulations.